Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells

@inproceedings{Andre2018AntiNKG2AMI,
  title={Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells},
  author={Pascale Andre and Caroline Denis and Caroline Soulas and Clarisse Bourbon-Caillet and Julie Lopez and Thomas Arnoux and Mathieu Bl{\'e}ry and C{\'e}cile Bonnafous and Laurent Gauthier and Ariane Morel and Benjamin Rossi and Romain Remark and Violette Breso and Elodie Bonnet and Guillaume Habif and Sophie Guia and Ana Ines Lalanne and Caroline Hoffmann and Olivier Lantz and J{\'e}r{\^o}me Fayette and Agn{\`e}s Boyer-Chammard and Robert Zerbib and Pierre Dodion and Hormas Ghadially and Maria N. Jure-Kunkel and Yannis Morel and Ronald Herbst and Emilie Narni-Mancinelli and Roger B. Cohen and Eric Vivier},
  booktitle={Cell},
  year={2018}
}
Checkpoint inhibitors have revolutionized cancer treatment. However, only a minority of patients respond to these immunotherapies. Here, we report that blocking the inhibitory NKG2A receptor enhances tumor immunity by promoting both natural killer (NK) and CD8+ T cell effector functions in mice and humans. Monalizumab, a humanized anti-NKG2A antibody, enhanced NK cell activity against various tumor cells and rescued CD8+ T cell function in combination with PD-x axis blockade. Monalizumab also… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 53 REFERENCES

platinum-based therapies. Cancer

  • C. Viant, A. Fenis, G. Chicanne, B. Payrastre, S. Ugolini, E. Vivier
  • Nat. Commun
  • 2014
Highly Influential
4 Excerpts

Natural killer cells and other innate lymphoid cells in cancer

  • L. Chiossone, Dumas, P.-Y, M. Vienne, E. Vivier
  • Nat. Rev. Immunol
  • 2018
1 Excerpt

Similar Papers

Loading similar papers…